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Available online 2 August 2016MicroRNA-29a (miR-29a) has been extensively studied in tumor biology and ﬁbrotic diseases, but little is known
about its functional roles in vascular smooth muscle cell (VSMC) differentiation from embryonic stem cells
(ESCs). Using well-established VSMC differentiation models, we have observed that miR-29a induces VSMC dif-
ferentiation frommouse ESCs by negatively regulating YY1, a transcription factor that inhibits muscle cell differ-
entiation and muscle-speciﬁc gene expression. Moreover, gene expression levels of three VSMC speciﬁc
transcriptional factors were up-regulated by miR-29a over-expression, but down-regulated by miR-29a inhibi-
tion or YY1 over-expression. Taken together, our data demonstrate that miR-29a and its target gene, YY1, play
a regulatory role in VSMC differentiation from ESCs in vitro and in vivo.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Smoothmuscle cells (SMCs) form the walls of blood vessels, provid-
ing the healthy vessel with its structure and contributing to the forma-
tion and progression of atherosclerotic plaques. Alterations in the
normal structure or function of the differentiated VSMCs play a major
role in a number of diseases, including atherosclerosis, cancer, and hy-
pertension (Owens et al., 2004). A better understanding of the mecha-
nisms and molecular regulation of VSMC differentiation is needed for
both prevention and treatment of these diseases.
Stem cells are long-lived cells with a remarkable capability of both
self-renewal and differentiation into multiple specialized cell types
(Weissman, 2000). ESCs are pluripotent stem cells derived from the
inner cell mass of a blastocyst (Thomson et al., 1998). Several in vitro
models have been well established to understand the regulation of
VSMC differentiation, but the underlying molecular mechanisms have
not been fully clariﬁed (Xie et al., 2011).
MicroRNAs (miRs) are small non-coding RNAs (~22 nucleotides)
that bind to complementary sites of their target mRNAs and inhibit
their translation (Hutvagner et al., 2001; Rossi, 2005). They are diverse
in sequence and expression patterns (Ambros, 2001). In recent studies,.
ally to this work.
. This is an open access article undermiRs have been suggested to play a major role in regulating gene ex-
pression in most organisms and have been implicated in regulating
the self-renewal and differentiation program of stem cells (Ivey et al.,
2008;Martinez andGregory, 2010). Emerging evidence clearly suggests
that miRs play a broad role in multiple aspects of endothelial biology,
and have been proven to be critical in mediating endothelial cell (EC)
differentiation (Zhou et al., 2014). Previous studies have shown that
miRs can affect VSMC biology, including phenotypic switching, prolifer-
ation, and migration. Especially, miR-143/miR-145, miR-21, and miR-
133 have been reported to play a role in VSMC differentiation
(Robinson and Baker, 2012).
MicroRNA-29a (miR-29a) has been extensively investigated in dif-
ferent ﬁelds. Roberta et al. reported that miR-29a is signiﬁcantly associ-
ated with hypertrophy and ﬁbrosis, suggesting that miR-29a can be a
potential biomarker for hypertrophic cardiomyopathy (Roncarati et
al., 2014). MiR-29a also functions as a negative regulator of collagen
gene expression. Maintaining miR-29a expression would have beneﬁ-
cial effects in ﬁbrotic diseases (van Rooij et al., 2008). As an important
regulator of the inﬂammatory response, miR-29a regulates scavenger
receptor expression by targeting lipoprotein lipase (Chen et al., 2011).
In addition, miR-29a has been implicated in malignancies (Pekarsky
and Croce, 2010) and found to be highly expressed in the endothelium
(Poliseno et al., 2006). However, little is known about the functional in-
volvement of miR-29a in VSMC biology.
In the current study, we aimed to investigate the biologic activity of
miR-29a in VSMC differentiation from ESCs and have uncovered a novelthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sion of a transcription factor, YY1.2. Materials and methods
2.1. Materials
Antibodies against YY1 (66281-1-Ig), α smooth muscle actin
(SMαA, 60255-1-Ig), were purchased from Proteintech, USA. Antibody
against Smooth Muscle Myosin Heavy Chain (SM-MHC, AHP1117)
was from AbD Serotec. Antibodies against SM22α (SM22, Ab14106)
and h1-calponin (Calponin, Ab46794) were from Abcam, UK. Antibod-
ies against GAPDH were from Sigma. All secondary antibodies were
from Santa Cruz Biotech.2.2. Cell culture and differentiation
Detailed protocols for mouse embryonic stem (ES) (ES-D3 cell line,
CRL-1934; ATCC, Manassas, VA) cell culture and VSMC differentiation
were described in our previous studies (Pepe et al., 2010; Wang et al.,
2012; Xiao et al., 2011; Xiao et al., 2007; Zheng et al., 2013). Brieﬂy,
ESCs were dispersed on gelatin (Sigma) coated ﬂasks and cultured in
ES culture medium (CM) that included knockout Dulbecco's Modiﬁed
Essential Medium (DMEM, Gibco), 10% Embryomax Foetal Bovine
Serum (FBS, Gibco), 10 ng/ml Leukaemia Inhibitor Factor (LIF,
Millipore), 0.1 mM 2-mercaptoethanol (2-ME, Sigma), 100 U/ml peni-
cillin and 100 μg/ml streptomycin (Life technologies) and 2 mM Gluta-
mine (Sigma). Cells were split every 3 days in a ratio of 1:4. For VSMC
differentiation, undifferentiated ES cells were seeded onmouse collagen
IV (5 μg/ml, Corning) coated ﬂasks or plates in differentiation medium
(DM) that containsα-minimal essentialmedium(aMEM,Gibco) supple-
mented with 10% FBS, 0.05 mM 2-ME, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM glutamine. DM was refreshed every day
after the second day of differentiation. The cells were cultured in DM
for 4–8 days before harvested and for further analysis.2.3. Western blot analysis
Cells were harvested and lysed in lysis buffer (RIPA, Beyotime Insti-
tute of Biotechnology) supplemented with protease inhibitors (PMSF,
Aladdin). Equal amounts of protein (40 μg) were resolved by SDS-PAGE
with 5%–12% Tris-Glycine gel (Invitrogen) and subjected to standard
western blot analysis (Zheng et al., 2013). The results were subjected to
densitometric analysis with Image J software. To ensure equal protein
loading, GAPDH proteinwas used as an internal control. The relative pro-
tein expression level was deﬁned as the ratio of target protein expression
level to GAPDHexpression levelwith that of the control sample set as 1.0.Table 1
Primer sets used in the present study.
Gene names Forward (5′–3′) Reverse (5′–3′)
18s rRNA AAACGGCTACCACATCCAG CCTCCAATGGAT
U6 snRNA GATGACACGCAAATTCGTG miRNA universa
miR-29a CGGACTGATTTCTTTTGGTGTTCAG miRNA universa
SMαA TCCTGACGCTGAAGTATCCGAT GGCCACACGAAG
SM22α GAT ATG GCA GCA GTG CAG AG AGT TGG CTG TC
h1-Calponin GGT CCT GCC TAC GGC TTG TC TCG CAA AGA A
SM-myh11 AAG CAG CCA GCA TCA AGG AG AGC TCT GCC AT
YY1 GTGGTTGAAGAGCAGATCATTGG GTGCAGCCTTTA
SRF CCTACCAGGTGTCGGAATCTGA TCTGGATTGTGG
Myocd TCAATGAGAAGATCGCTCTCCG GTCATCCTCAAA
MEF-2C AAGCCAAATCTCCTCCCCCTAT TGATTCACTGAT2.4. Real-time quantitative PCR (RT-qPCR) for mRNA and microRNAs
Real-time quantitative PCR (RT-qPCR) was performed as previously
described (Chen et al., 2011; Zhang et al., 2010). Brieﬂy, total RNA con-
taining miRs was extracted from cells using Trizol according to the
manufacturer's instructions. Total and miR-speciﬁc cDNA synthesis
was performed with Prime Script RT Master Mix Perfect Real Time kit
(DRR036A, Takara, China) and miRNA RT-PCR Kit (RR716, Takara,
China), respectively. The RT-qPCR reaction was run on an ABI Prism
7500 system following the instructions provided in the Takara premix
Ex Taq II kit (DRR820A, Takara, China) or miRNA RT-PCR Kit (RR716,
Takara, China). The primer sequences for VSMC differentiation genes
(SMA, SM22, SMMHC, Calponin) and related transcription factors
(SRF, MYO, MEF-2C) were the same as used in our previous study (Yu
et al., 2015; Zhao et al., 2015a; Zheng et al., 2013). All the primer se-
quence are shown in Table 1 and synthesized by Sangon, China. Relative
mRNA or miR expression levels were deﬁned as the ratio of the target
gene expression level or miR expression level to 18S or U6 snRNA ex-
pression level, respectively, with that of the control sample set as 1.0.2.5. MicroRNA and plasmid transfection
Either miR-29a inhibitor or miR-29a precursor (Pre-miR-29a) and
miRNA negative controls were transfected into 4-day differentiating
ES cells using Lipofectamine 3000 (Thermo Fisher Scientiﬁc), in accor-
dancewith themanufacturer's protocol. Transfected cells were cultured
for 48–96 h in the DM to allow VSMC differentiation. All miRNAs inhib-
itors or precursors and respective negative controls were purchased
from BAIAO. Control (pCMV6-Entry) or a YY1 overexpression plasmid
(pCMV6-Entry-YY1, Origene) were transfected into differentiating ES
cells using Lipofectamine 3000 according to themanufacturer's instruc-
tions. MiRNA (pre-miR-29a or miR negative control) and plasmid
(pCMV6-Entry or pCMV6-Entry-YY1) co-transfection experiments
were performed using jetPRIME® (Polyplus, SA).2.6. Luciferase reporter assay
For the luciferase reporter assays, ES cells (6 × 104 per well) were
seeded into collagen-coated 12-well plates and cultured in DM 96 h
later, cells were transfected with the luciferase reporter plasmids
(pGL3-SRF-Luc, pGL3-MEF-2c-Luc or pGL3-Myocd-Luc generated in
our previous study (Huang et al., 2013), 0.33 μg/well) and pre-miR-
29a, or miR negative control (100 nM) using jetPRIME® (Polyplus). A
Renilla reporter plasmid (0.1 μg/well, Promega) was included in all
transfection assays as an internal control. Luciferase and Renilla activity
assays were analyzed 48 h after transfection. Relative luciferase unit
(RLU) was deﬁned as the ratio of luciferase activity to Renilla activity
with that of control set as 1.0.GenBank accession numbers
CCTCGTTA NR_003278.3
l reverse primer (Invitrogen, A11193-051) NR_003027.2
l reverse primer (Invitrogen, A11193-051) MIMAT0004631
CTCGTTATAG NM_007392.3
T GTG AAG TC NM_011526.5
TG ATC CCG TC NM_009922
G TCC TCC AC NM_013607
TGAGGGCAA NM_009537.3
AGGTGGTACC NM_020493.2
GGCGAATGC NM_145136.4
GGCATCGTGT NM_001170537.1
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All animal protocols were reviewed and approved by the Zhejiang
University Animal Care and Use Committee. All methods were carried
out in accordance with the approved guidelines. Control (miR negative
control) ormiR-29a overexpressing (pre-miR-29a) ES cells labeledwith
green ﬂuorescence, PKH67 (Sigma), were induced to differentiate into
VSMCs in vivo as described in our previous studies (Huang et al., 2013;
Xiao et al., 2012; Yu et al., 2015; Zhao et al., 2015b). Brieﬂy,miR negative
control or miR-29a overexpressing ES cells (106 cells in 50 μl) were
mixed with 50 μl of Matrigel™ (Becton Dickinson Labware) at 4 °C,
and subcutaneously injected into C57BL/6J mice. After 10–13 days,
mice were euthanized and the implants (Matrigel™ plugs) were har-
vested and frozen in liquid nitrogen for future using. Part of each
Matrigel™ plug was sectioned for detection of cell markers and the
remained was lysed and extracted for total RNA or protein to examine
the expression levels of the indicated markers, respectively.
2.8. Fluorescent immunochemistry
For immunoﬂuorescent staining, sections were cut at 8 μm for opti-
mum cutting of temperature compound–embedded Matrigel™ im-
plants, every 40 μm along the longitudinal axis of Matrigel™ plugs and
numbered. Certain numbered sections (for instance, sections 5, 15 and
25) were subjected to immunohistological analyses with respective an-
tibodies. Brieﬂy, frozen sections were air-dried for at least 30 min,
followed by ﬁxation in cold acetone for 15 min. The sections were
then rinsed in PBS and blocked with 5% BSA in PBS (Gibco) for 1 h at
room temperature in a humid chamber. The incubation with primary
antibodies (SM-MHC, SMA) or IgG controls diluted in blocking buffer
was performed in a cold room (4 °C) overnight. Following incubation
with appropriate FITC or TRITC conjugated secondary antibodies, sec-
tions were then incubated with DAPI (1:1000, Sigma) for 5 min. Images
were assessed with an Axioplan 2 imaging microscope with Plan-
NEOFLUAR 20×, NA 0.5, objective lenses, AxioCam camera, and Axiovi-
sion software (all Carl Zeiss MicroImaging, Inc.) at room temperature.
Photoshop software (Adobe) was used to analyze the acquired images.Fig. 1.microRNA29a (miR-29a) was upregulated during mouse embryonic stem cells (ESC) dif
plates coated with collagen IV and cultured in VSMC differentiation medium (DM) for the indi
with primers speciﬁc for smoothmuscleα-actin (SMαA) (A), SM22 (B), smoothmusclemyosin
and served as negative controls. The data presented here are the mean ± SEM of 3 independeThe percentage of PKH67-labeled SM-MHC positive cells per ﬁeld were
counted by two well-trained independent investigators blinded to the
treatments, from four randomhigh power ﬁelds (200×) in each section,
three sections from each implant and four implants for each group.
2.9. Statistical analysis
Data were expressed as mean ± SEM and analyzed using a two-
tailed student's t-test for two-group comparison or one-way ANOVA
followed by Tukey's HSDmultiple comparison post-hoc test for compar-
ing different groups. A value of p b 0.05 was considered as statistically
signiﬁcant.
3. Result
3.1. miR-29a mediates VSMC differentiation from ESCs in vitro
To induce VSMC differentiation, ES cells were reseeded into 6-well
plate coated with collagen IV and cultured in VSMC differentiation me-
dium for 2 to 8 days. Consistently, gene expression levels of VSMC spe-
ciﬁc markers including smoothmuscle α-actin (SMαA) (Fig. 1A), SM22
(Fig. 1B), and smooth muscle myosin heavy chain (SM-MHC) (Fig. 1C)
were signiﬁcantly upregulated during differentiation. Importantly,
miR-29a expression was induced from day 2 of differentiation, and
peaked at day 4 of differentiation (Fig. 1D), suggesting a role of miR-
29a in VSMC differentiation.
Loss-of-function and gain-of-function experiments were used to in-
vestigate whether miR-29a was necessary for VSMC differentiation.
Gain-of-function experiments using miR-29a precursor (pre-miR-29a)
were performed in differentiating ES cells. Data showed both gene and
protein levels (Fig. 2A and B) of three out of four differentiation speciﬁc
markers (SMαA, SM22, and SM-MHC) were signiﬁcantly increased by
miR-29a overexpression. We also observed an increase in h1-calponin
mRNA induced by miR-29a over-expression, yet it was not statistically
signiﬁcant. On the other hand, data from the loss-of-function experi-
ments by using miR-29a inhibitor revealed that miR-29a knockdown
signiﬁcantly inhibited the gene and protein expression of SMαA,ferentiation towards vascular smooth muscle cells (VSMCs). Cells were cultured in 6-well
cated times. Total RNA including miRs were harvested and subjected to RT-qPCR analyses
heavy chain (SM-MHC) (C) andmiR-29a (D). Day 0 sampleswere undifferentiated ES cells
nt experiments. #p b 0.01, *p b 0.05.
Fig. 2.miR-29a promotes VSMC differentiation from ESCs. (A and B) miR-29a overexpression signiﬁcantly increases VSMC marker gene expression levels. Day 3–4 differentiating ESCs
were transfected with pre-miR-29a or miR negative control and cultured in VSMC DM for 48–72 h. (C and D) miR-29a inhibition decreases VSMC marker expression levels. Day 3–4
differentiating ESCs were transfected with miR-29a inhibitor or miR negative control and cultured in VSMC DM for 48 h. Total RNAs and proteins were harvested and subjected to RT-
qPCR (A and C) and western blot (B and D) analyses, respectively. The data presented here are representative (left panel in B and D) or mean ± S.E.M. of 4 independent experiments.
*p b 0.05, #p b 0.01.
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cally signiﬁcant, a decrease in SM-MHC protein level was observed in
the cells transfected with miR-29a inhibitor, suggesting a role of miR-
29a in VSMC differentiation from stem cells in vitro.
3.2. miR-29a is likely to promote VSMC differentiation in vivo
To investigate whether or not miR-29a can promote VSMC differen-
tiation in vivo,Matrigel™mixedwith control ormiR-29a overexpressing
ESCs was injected subcutaneously into the mouse. Immunoﬂuorescent
analyses (Fig. 3A and B) showed that more SM-MHC-positive cells
were presented in theMatrigel™ plugs implantedwithmiR-29a overex-
pressing ESCs, although no signiﬁcant difference was observed between
the two groups. Moreover, data from RT-qPCR (Fig. 3C) and western
blotting (Fig. 3D) analysis revealed that overexpression of miR-29a
increased both the gene and protein levels of smooth muscle differenti-
ation speciﬁc markers in vivo. Taken together, these data suggest a
regulatory role of miR-29a in VSMC differentiation from stem cells
both in vitro and in vivo.
3.3. Target gene, YY1, is negatively regulated by miR-29a
By utilizing the TargetScan program (http://www.targetscan.org),
we have observed that miR-29a has complementary sequences to
YY1's 3′UTR mRNA. All miR-29 family members have been previously
predicted to hybridize to an evolutionarily conserved site within the
YY1 3′UTR among vertebrate species (Wang et al., 2008). Moreover,
miR-29 can speciﬁcally interact with the 3′UTR of YY1 mRNA to inhibit
its translation (Wang et al., 2011). Therefore, we examined whether or
not miR-29a modulates YY1 during VSMC differentiation from ESCs.
Consistent with previous ﬁndings, our data revealed that YY1 gene
(Fig. 4C) and protein (Fig. 4D and E) levels were signiﬁcantly upregulat-
ed by inhibition of miR-29a (Fig. 4B), whereas its protein expression
level (Fig. 4D and E)was signiﬁcantly downregulated by overexpressionof miR-29a (Fig. 4A). The result conﬁrms that YY1 is negatively regulat-
ed by miR-29a during VSMC differentiation from ESCs.
3.4. YY1 functions as a negative regulator of VSMC differentiation and res-
toration of YY1 impairs miR-29a-promoted VSMC differentiation
To investigate the potential role of YY1 in VSMC differentiation, we
over-expressed YY1 in the differentiating ESCs. YY1 overexpression sig-
niﬁcantly downregulated mRNA and protein expression of VSMC
markers (Fig. 5A and B), suggesting that YY1 is a negative modulator
of VSMC differentiation. To further study the functional involvement
of YY1 in miR-29a-mediated VSMC differentiation, miR-29a and YY1
were co-transfected in the differentiating ESCs. Data from RT-qPCR
(Fig. 5C) and western blot (Fig. 5D and E) analyses revealed that resto-
ration of YY1 expression in the presence of miR-29a over-expression al-
most abolished VSMC speciﬁc gene upregulation, suggesting that miR-
29a-mediated VSMC differentiation is largely dependent on the repres-
sion of YY1.
3.5. miR-29a mediates VSMC differentiation through modulation of VSMC
transcription factors
Serum response factor (SRF), myocyte-speciﬁc enhancer factor 2c
(MEF-2C) andmyocardin (Myocd) arewell-known transcription factors
for VSMC gene regulation. Particularly, SRF and its co-activator,
Myocardin, interact with the SRF binding element (CArG box) within
the promoter of SMC genes and the interaction regulates transcriptional
activation of SMC genes (Miano, 2003). Therefore, we investigated if
miR-29a modulates these three transcription factors during VSMC dif-
ferentiation from ESCs. Our data showed that gene expression levels
of all three transcription factors were signiﬁcantly upregulated by
miR-29a overexpression (Fig. 6A), whereas inhibition of miR-29a
signiﬁcantly down-regulates their expression levels except for MEF2C
(Fig. 6B). Such a notion has been further recapitulated by luciferase
Fig. 3.miR-29a promotes VSMCs differentiation in vivo. Matrigel™mixed with ESCs transfected with miR negative control or pre-miR-29a was injected subcutaneously into mouse and
harvested for further experiments. (A and B)Matrigel™ plugs with ESCs transfected with pre-miR-29a showedmore SMαA/SM-MHC positive cells. Matrigel™ plugs were sectioned and
subjected to immunoﬂuorescence staining using antibodies against SMαA/SM-MHC (Blue is DAPI, Red is SMαA/SM-MHC). (C and D) VSMC marker gene expressions within Matrigel™
implants. Total RNA and protein samples were extracted and subjected to RT-qPCR (C) and western blot (D) analyses. The data presented here are representative or mean ± S.E.M of 3
repeats at least. *p b 0.05, #p b 0.01.
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Data shown in Fig. 6D revealed that the miR-29a overexpression signif-
icantly increased gene promoter activities of SRF andMyocd, but not the
MEF2C, indicating that miR-29a upregulated transcriptional activity of
SRF and Myocd genes. Interestingly, a previous study has suggested a
potential interplay between YY1 and SRF in transcriptional regulation
of SM-MHC and SM22 genes (Itoh et al., 2001). Indeed, our results
showed that YY1 negatively regulated SRF, MEF-2C andMyocd gene ex-
pression (Fig. 6C). Taken together, the above data have suggested that
miR-29a promotes VSMC differentiation from ESCs through targeting
and suppressing the transcription factor, YY1. As YY1 inhibits VSMC dif-
ferentiation and gene expression of VSMC speciﬁc transcription factors,
SRF andMyocd, themiR-29a dependent suppression of YY1, in turn, ac-
tivates VSMC differentiation.
4. Discussion
Alteration in the normal structure or function of differentiated
VSMCs plays a major role in a number of diseases, including atheroscle-
rosis, hypertension, and cancer. The underlying molecular mechanisms
of VSMCdifferentiation remain to be elucidated. Accumulating evidence
has demonstrated that the gene regulatory programof VSMCdifferenti-
ation from pluripotent stem cells is orchestrated by a coordinated mo-
lecular network with various signaling pathways and molecules
involved, such as mechanical forces, contractile agonists, extracellular
matrix components (laminin and type I and IV collagen), Matrix Metal-
loproteinases (Chen et al., 2013), neuronal factors, reactive oxygen spe-
cies (Zhou et al., 2013), endothelial SMC interactions, thrombin, TGF
family, notch family (Tang et al., 2010), and miRs. Although all ofthese factors have been shown to promote expression of at least some
VSMC marker genes in cultured cell systems (Owens et al., 2004; Xie
et al., 2011), our understanding of the molecular mechanisms underly-
ing VSMC differentiation from ESCs is still far from complete. In this
study, we revealed an important role of miR-29a in regulating VSMC
speciﬁc gene expression and VSMC differentiation from ESCs in vitro
and in vivo. We presented the ﬁrst evidence to support a functional
role of YY1 in VSMC differentiation and VSMC speciﬁc gene regulation.
We also provided the evidence to support that the identiﬁed target
gene of miR-29a, YY1, functions as an important VSMC differentiation
gene repressor during VSMC differentiation from stem cells.
miR-29a has been extensively studied in different ﬁelds. miR-29a
has been reported to be associated with cardiac hypertrophy and ﬁbro-
sis (Roncarati et al., 2014), and functions as a negative regulator of ex-
tracellular matrix remodeling (van Rooij et al., 2008). We have
previously reported that miR-29a can also act as an important regulator
of the inﬂammatory response (Chen et al., 2011). In the current study,
using miRNA gain/loss-of-function analyses and a well-established in
vitro VSMC differentiation model, we conﬁrmed a regulatory role for
miR-29a in VSMC differentiation from ESCs. An important role of miR-
29a in VSMC differentiation has been further conﬁrmed in our well-
established in vivo VSMC differentiation model with Matrigel™
implantation.
One of the new ﬁndings in the current study is that we have identi-
ﬁedYY1 as the target gene ofmiR-29a duringVSMCdifferentiation from
ESCs. YY1 (also known as Yin Yang1, NF-E1, UCRBP and CF1), a ubiqui-
tous and dual-function GLI-Kruppel zinc ﬁnger transcription factor, was
ﬁrst identiﬁed on the basis of its capacity to negatively regulate the
adeno-associated virus P5 promoter (Shi et al., 1991). Recent studies
Fig. 4. YY1 is negatively regulated by miR-29a during ESC differentiation. (A) miR-29a over-expression with pre-miR-29a in differentiating ESCs; (B) miR-29a inhibition with miR29a
inhibitor in differentiating ESCs. (C–E) YY1 is adversely modulated by miR-29a during SMC differentiation from ESCs. Day 3 differentiating ESCs were transfected with pre-miR-29a
(A), miR29a inhibitor (B), or respective miR negative controls, and cultured for further 48 h. Total RNA and protein were harvested and subjected to RT-qPCR (A–C) and western blot
(D–E) analyses, respectively. The data presented here are representative (D) or mean ± S.E.M. of 3 independent experiments. #p b 0.01, *p b 0.05.
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dent of its DNA binding activity (Deng et al., 2010). It has been reported
that YY1 is an important inhibitor of muscle cell differentiation andFig. 5.YY1 acts as a VSMCdifferentiation repressor and re-activation of YY1 impairs the promot
from ESCs. Day 3–4 differentiating ES cells were transfectedwith control (pCMV6-Entry) or YY1
Total RNA and proteinwere harvested and subjected to RT-qPCR (A) andwestern blot (B) analy
three independent experiments. #p b 0.01, *p b 0.05. (C–E) YY1 re-activation abolished VSMC g
pre-miR-29a, YY1 over-expression (pCMV6-Entry-YY1) plasmids, and/or respective controls (m
and protein were harvested and subjected to RT-qPCR (C) andwestern blot (D–E) analyses, res
three independent experiments. *p b 0.05 (versus double negative controls); #p b 0.05 (pCMVexpression of muscle-speciﬁc genes (Ellis et al., 2002). Another study
has reported that VSMC phenotype is also regulated by the YY1 (Favot
et al., 2005), yet the potential interplay between YY1 and VSMC biologyive effects ofmiR-29a on VSMCdifferentiation. (A and B) YY1 inhibits VSMCdifferentiation
over-expression plasmid (pCMV6-Entry-YY1), and cultured in VSMCDM for another 48 h.
ses, respectively. The data presented here are representative (Left in B) ormean± S.E.M. of
ene expression induced bymiR-29a. Day 3–4 differentiating ESCs were co-transfectedwith
iR negative control or pCMV6-Entry), and cultured inVSMCDM for 48 h further. Total RNA
pectively. The data presented here are representative (Left in B and D) or mean± S.E.M. of
6-Entry-YY1 versus pCMV6-Entry in the presence of pre-miR-29a).
Fig. 6.Modulation of VSMCdifferentiation related transcription factors (TF) bymiR29a and YY1. (A and B)Gene expression levels of serum response factor (SRF),myocardin (Myocd) and
myocyte-speciﬁc enhancer factor 2c (MEF2C) were signiﬁcantly upregulated by miR-29a overexpression (A), but dramatically down-regulated by miR-29a inhibition (B) and YY1 over-
expression (C), respectively. Day 3–4 differentiating ESCs were transfected with pre-miR-29a (A), miR-29a inhibitor (B), pCMV6-Entry-YY1 (C), or respective controls (miR negative
control or pCMV6-Entry), and cultured in VSMC DM for 48 h further. Total RNA was harvested and subjected to RT-qPCR analyses with indicated primers. The data presented here are
mean ± SEM of 3 independent experiments. #p b 0.05, *p b 0.01 (vs control). (D) Promoter activities of SRF, Myocd and MEF2C genes were enhanced by miR-29a. Day 3–4
differentiating ESCs were transfected with the indicated luciferase reporter plasmids [pGL3-SRF-Luc (SRF), pGL3-MEF2c-Luc (MEF2C), or pGL3-Myocd-Luc (Myocd)] (0.25 μg/well, 24-
well plate) and miR negative control or pre-miR-29a (25 pmol/well). Renilla plasmid (20 ng/well) was included as a control. Luciferase activity assays were detected 48–72 h after
transfection. The data presented here are mean ± SEM of 3 independent experiments. #p b 0.05, *p b 0.01 (vs control).
283M. Jin et al. / Stem Cell Research 17 (2016) 277–284is still unclear and needs further investigation (Aikawa, 2007). In the
current study, we have observed that YY1 is negatively regulated by
miR-29a, and re-activation of YY1 impairs VSMC gene activation in-
duced by miR-29a over-expression, supporting an important role of
YY1 in miR-29a-mediated VSMC differentiation from ESCs.Fig. 7. Regulatory role ofmiR-29a inVSMCdifferentiation.MiR-29a targets YY1, de-suppressing
differentiation from stem cells both in vivo and in vitro.5. Conclusion
In the current study, we reported a novel function of miR-29a in
VSMC differentiation from stem cells in vitro and in vivo, and provided
comprehensive evidence to support that YY1 is a genuine mRNA targetits negative regulation of transcription factors (SRF,MEF-2C,Myocd), resulting in the VSMC
284 M. Jin et al. / Stem Cell Research 17 (2016) 277–284of miR-29a during VSMC differentiation. Moreover, our data suggest
that YY1 is a negative regulator of VSMC related transcription factors
(SRF, Myocd, andMEF-2C), and repression of YY1 bymiR-29a is the un-
derlying mechanism of miR-29a-mediated VSMC differentiation from
ESCs (Fig. 7).
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